Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Duobrii in plaque psoriasis
NCT02462083Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of halobetasol propionate + tazarotene in plaque psoriasis, sponsored by Valeant Pharmaceuticals. Primary endpoint: Percentage of Participants Who Experienced Grade 3 Local Skin Reactions at 52 weeks. Started Aug 2015; status: completed.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02462083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462083.